Provided is a method for producing pluripotent stem cells from somatic cells, comprising the steps of (1) seeding somatic cells in a container comprising at least one compartment configured to permit gathering two or more somatic cells; (2) bringing a reprogramming factor into contact with the somatic cells; and (3) culturing the somatic cells in contact with the reprogramming factor in a state where the two or more somatic cells are gathered in the compartment.

In related-art methods of differentiating pluripotent stem cells into a desired cell type, there has not been established a differentiation induction method using human ES/iPS cells and being stable and highly efficient. The use of complicated culture steps is a large problem. In addition, there are also large problems in, for example, that the speed of cell differentiation is low, and hence long-period culture is required, and that the differentiation efficiency is low, and hence it is difficult to obtain a sufficient number of required cells. A method of inducing differentiation into a desired cell type, which induces differentiation within a short period of time and with high efficiency by the use of a Sendai virus vector capable of expressing a transcription factor, and as required, the use of a pluripotent stem cell in which an expression amount of a POU5F1 protein has been substantially removed or reduced, is provided.

The present disclosure pertains to production of a virus vector plasmid. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced does not have to be a plasmid.

The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.

The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.

An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.

The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.

Described are methods of preparing precursor cell-derived induced pluripotent stem cells (iPSCs) and methods of generating iPSC-derived gd T-cells. The invention also includes cell populations comprising the iPSCs, cell populations comprising the iPSC-derived gd T-cells, pharmaceutical compositions comprising the cell populations, and methods of treating cancer comprising administration of the cell population or pharmaceutical composition thereof.

The present invention relates to a method of manufacturing an alveolar organoid using alveolar cell-derived induced pluripotent stem cells. The alveolar organoid manufactured according to the present invention is differentiated from the human alveolar cell-derived induced pluripotent stem cells, and thus induced pluripotent stem cells may efficiently differentiate into alveolar organoids due to the epigenetic memory of alveolar cells. Therefore, the alveolar organoids are expected to be effectively used for research on the pathological process of respiratory diseases, screening for finding therapeutic drugs, and the like.

A method of manufacturing autologous cardiac lineage cells, the method includes receiving a patient-specific sample from a subject, producing a plurality of fibroblast cells as a function of the patient-specific sample, wherein producing the plurality of fibroblast cells includes transferring the patient-specific sample to a first growth media, generating a plurality of induced pluripotent stem cells (iPSCs) as a function of the plurality of fibroblast cells, wherein generating the plurality of iPSCs includes identifying a plurality of confluent iPSCs from the plurality of iPSCs, and differentiating the plurality of iPSCs into a plurality of cardiac lineage cells, wherein differentiating the plurality of iPSCs into a plurality of cardiac lineage cells includes performing a two-dimensional (2D) expansion process on the plurality of confluent iPSCs and performing a three-dimensional (3D) expansion process on the plurality of 2D-expended confluent iPSCs.